3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
3
Phase 3
2
Phase 2
2
Phase 1/2
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Myeloid
2
Other hematologic neoplasm
1
Conditions
Primary Myelofibrosis
2
Myeloproliferative Disorders
2
Interventions
Imatinib Mesylate
28
nilotinib
21
Cytarabine
21
Methotrexate
16
Hydroxyurea
15
Cyclophosphamide
15
Busulfan
15
Peripheral Blood Stem Cell Transplantation
13
ruxolitinib
11
Etoposide
11
Whole-Body Irradiation
10
fludarabine phosphate
9
fludarabine
9
Tacrolimus
9
Mycophenolic Acid
9
Daunorubicin
9
Idarubicin
8
Radiotherapy
7
Mitoxantrone
7
Interferon-alpha
7
Cyclosporine
6
peginterferon alfa-2a
5
bosutinib
5
asciminib
5
Melphalan
5
Azacitidine
5
merphos
4
luspatercept
4
Thioguanine
4
Filgrastim
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
fedratinib
×
Myeloid
×
Clear all
NCT03952039
2025-08-28
FREEDOM2
Celgene
Phase 3
Completed
202 enrolled
23 charts
NCT03755518
2024-12-12
FREEDOM
Celgene
Phase 3
Terminated
38 enrolled
23 charts